Qiagen N.V.

ots Ad hoc-Service: QIAGEN N.V. PreAnalytiX Launches First Product for RNA Stabilization

Ad hoc-announcement. The sender is solely responsible for the contents of this announcement. -----------------------------------------------------

    Hombrechtikon, Switzerland (ots Ad hoc-Service) -      

    PreAnalytiX GmbH, an equally owned joint venture between QIAGEN N.V. (Nasdaq: QGENF, Frankfurt Neuer Markt: QIA, Easdaq: QGEN) and Becton Dickinson and Company (NYSE: BDX), announced today the launch of its first product, the PAXgene(TM) Blood RNA System. Due to the significant information content of RNA, this molecule is widely analyzed in clinical research, molecular diagnostics and genomics. Unlike DNA, RNA is highly unstable. By consolidating and integrating the key steps of sample collection, stabilization and purification, the PAXgene(TM) Blood RNA System is designed to minimize the chronic problems associated with preanalytical process variability and to eliminate much of the unpredictability that has been a critical limitation in RNA analysis. The PAXgene(TM) Blood RNA System combines BD's leadership in the area of sample collection for clinical laboratories with QIAGEN's leadership in the area of stabilization and purification of nucleic acids. A first of its kind, it employs an evacuated blood collection device with proprietary PreAnalytiX reagent that, in a single blood draw, rapidly protects and stabilizes RNA. The system eliminates the need for expensive and immediate freezing, allowing transport and storage at room temperature for periods well exceeding what is required in sample logistics. PreAnalytiX believes that the PAXgene(TM) Blood RNA System will have a profound impact in clinical research, molecular diagnostics and genomics, especially in high-volume clinical trials where complex sample logistics, multiple sites and long transport times are issues. As predictive, prognostic, and diagnostic applications for gene expression analysis continue to rapidly evolve, PreAnalytiX believes that the PAXgene(TM) Blood RNA System will enable faster, more accurate, and higher quality nucleic acid test results. PreAnalytiX is pioneering integrated systems to standardize the collection, stabilization, isolation and purification of RNA and DNA from a range of samples, including whole blood, bone marrow, and a multitude of tissues.


    PreAnalytiX GmbH Dr. Helge Bastian Vice President +49 (2103) 29 16260 e-mail: h.bastian@de.QIAGEN.com

    WKN: 901626; Index: NEMAX50 Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, München, Hannover und Stuttgart

End ----------------------------------------------------- Internet: http://recherche.newsaktuell.de

Original-Content von: Qiagen N.V., übermittelt durch news aktuell

Weitere Meldungen: Qiagen N.V.

Das könnte Sie auch interessieren: